Zevra Therapeutics Inc’s filing revealed that its Director Watton Corey Michael acquired Company’s shares for reported $3958.0 on Oct 11 ’24. In the deal valued at $7.92 per share,500 shares were bought. As a result of this transaction, Watton Corey Michael now holds 1,500 shares worth roughly $12165.0.
Then, Clifton R. LaDuane bought 2,000 shares, generating $13,540 in total proceeds. Upon buying the shares at $6.77, the CFO & Treasurer now owns 18,469 shares.
Before that, Anderson Thomas bought 10,000 shares. Zevra Therapeutics Inc shares valued at $68,065 were divested by the Director at a price of $6.81 per share. As a result of the transaction, Anderson Thomas now holds 20,000 shares, worth roughly $0.16 million.
A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. Maxim Group also remained covering ZVRA and reiterated its “Buy” recommendation on September 24, 2024. JMP Securities started covering the stock on September 24, 2024. It rated ZVRA as “a Mkt outperform”.
Price Performance Review of ZVRA
On Friday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock fall -4.92% to $8.11. Over the last five days, the stock has lost -7.42%. Zevra Therapeutics Inc shares have fallen nearly -2.76% since the year began. Nevertheless, the stocks have risen 27.72% over the past one year. While a 52-week high of $9.76 was reached on 01/03/25, a 52-week low of $4.20 was recorded on 01/10/25. SMA at 50 days reached $8.75, while 200 days put it at $6.73.
Levels Of Support And Resistance For ZVRA Stock
The 24-hour chart illustrates a support level at 7.92, which if violated will result in even more drops to 7.74. On the upside, there is a resistance level at 8.35. A further resistance level may holdings at 8.60. The Relative Strength Index (RSI) on the 14-day chart is 41.09, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.16, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.60%. Stochastics %K at 38.19% indicates the stock is a holding.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2024-12-13, dropping by 40876.0 shares to a total of 4.07 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 4.11 million shares. There was a decline of -1.0%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 02, 2024 when Maxim Group resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $18.
